Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.

Shares of Novo Nordisk ( NVO 2.48%) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

As a Barclays analyst put it, it’s been a “slow-moving car crash”. Early supply shortages pushed patients to competitors, while Novo’s cautious marketing lagged behind Lilly’s aggressive, ...

Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...

Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...

(Reuters) -Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1. The one-time price will also be available through ...

CNBC's Karen Gilchrist discusses Novo Nordisk's new CEO and the pharma giant's move to cut its full-year guidance on weaker ...